Claim and source comparison
Comparison scope: Abstracts of Ferris 1977, Fisman 1981, Grossman 2005, Zahniser 1977 and Fisher 2001. Not a complete clinical or independent medical review.
· Bounded source comparison; not a complete clinical review or independent medical endorsement.
Uncontrolled human intervention study
Ferris 1977: In a four-week open deanol study in 14 people with dementia, some behavioral ratings improved; memory and other cognitive functions did not.
There was no concurrent control group; behavioral change does not establish a drug effect. This small historical study does not establish a cognitive dose or general safety for healthy people.
Source 1 · Abstract read
Human controlled trial; randomization not verified
Fisman 1981: A double-blind placebo-controlled trial studied 27 people with Alzheimer's disease. 6 of 13 in the drug group withdrew within 5 weeks because of side effects; no significant benefit was found.
Reported problems included drowsiness, slowing, increased confusion and mild blood-pressure elevation. The abstract does not verify randomization; 6/13 is not the adverse-event rate for all users. It does not justify self-directed dose reduction or timing advice.
Source 2 · Abstract read
Narrative review
Grossman 2005: A cosmetic review describes a 16-week skin study of 3% DMAE facial gel; this is not an oral DMAE trial.
A narrative review is not a new cognitive RCT. Results from a topical gel do not establish oral efficacy, safety or an acetylcholine-precursor mechanism.
Source 3 · Abstract read
Animal study
Zahniser 1977: Injected deanol did not increase whole-brain acetylcholine in rodents at the doses and times examined; a very high dose produced a limited increase in mouse striatum.
This animal experiment questions the proposed direct-precursor mechanism; it alone proves neither oral benefit nor lack of benefit in humans. Injection doses are not supplement recommendations.
Source 4 · Abstract read
Cell / laboratory study
Fisher 2001: Mouse embryos exposed in vitro to 250–750 µM DMAE for 26 hours developed facial and neural-tube defects.
This is not an oral-dose trial in pregnant humans; human risk magnitude or a safe dose cannot be calculated. It gives no reassurance for self-use in pregnancy. Use with neurological/psychiatric illness or medicines needs clinical assessment; missing interaction records do not mean safe.
Source 5 · Abstract read
2026-11-11 correction: Selected sources were compared for study design, product, measured outcome and safety limits. Generic dosing and mechanism-to-benefit inferences were removed; the first-publication date was preserved.
DMAE has not been established as an acetylcholine precursor or as improving focus or memory in healthy people. Older small studies were negative or uncertain; cosmetic use does not establish oral cognitive benefits.
Clinical Trials
Ferris 1977: In a four-week open deanol study in 14 people with dementia, some behavioral ratings improved; memory and other cognitive functions did not.
There was no concurrent control group; behavioral change does not establish a drug effect. This small historical study does not establish a cognitive dose or general safety for healthy people.
Fisman 1981: A double-blind placebo-controlled trial studied 27 people with Alzheimer's disease. 6 of 13 in the drug group withdrew within 5 weeks because of side effects; no significant benefit was found.
Reported problems included drowsiness, slowing, increased confusion and mild blood-pressure elevation. The abstract does not verify randomization; 6/13 is not the adverse-event rate for all users. It does not justify self-directed dose reduction or timing advice.
Grossman 2005: A cosmetic review describes a 16-week skin study of 3% DMAE facial gel; this is not an oral DMAE trial.
A narrative review is not a new cognitive RCT. Results from a topical gel do not establish oral efficacy, safety or an acetylcholine-precursor mechanism.
Zahniser 1977: Injected deanol did not increase whole-brain acetylcholine in rodents at the doses and times examined; a very high dose produced a limited increase in mouse striatum.
This animal experiment questions the proposed direct-precursor mechanism; it alone proves neither oral benefit nor lack of benefit in humans. Injection doses are not supplement recommendations.
Fisher 2001: Mouse embryos exposed in vitro to 250–750 µM DMAE for 26 hours developed facial and neural-tube defects.
This is not an oral-dose trial in pregnant humans; human risk magnitude or a safe dose cannot be calculated. It gives no reassurance for self-use in pregnancy. Use with neurological/psychiatric illness or medicines needs clinical assessment; missing interaction records do not mean safe.
Dose information and research limits
This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.
Sources
- Ferris SH, et al. (1977). Senile dementia: treatment with deanol. Journal of the American Geriatrics Society, 25(6), 241–244. PubMed · PMID 864168
- Fisman M, et al. (1981). Double-blind trial of 2-dimethylaminoethanol in Alzheimer's disease. The American Journal of Psychiatry, 138(7), 970–972. PubMed · PMID 7020434
- Grossman R. (2005). The role of dimethylaminoethanol in cosmetic dermatology. American Journal of Clinical Dermatology, 6(1), 39–47. PubMed · PMID 15675889
- Zahniser NR, et al. (1977). Is 2-dimethylaminoethanol (deanol) indeed a precursor of brain acetylcholine? A gas chromatographic evaluation. The Journal of pharmacology and experimental therapeutics, 200(3), 545-59. PubMed · PMID 850128
- Fisher MC, et al. (2001). Inhibitors of choline uptake and metabolism cause developmental abnormalities in neurulating mouse embryos. Teratology, 64(2), 114-22. PubMed · PMID 11460263
Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory
Frequently Asked Questions
DMAE has not been established as an acetylcholine precursor or as improving focus or memory in healthy people. Older small studies were negative or uncertain; cosmetic use does not establish oral cognitive benefits.
There is no validated cognitive dose for DMAE. Total bitartrate salt weight is not the active DMAE amount; equivalent cognitive effects at lower milligrams of the salt have not been established.
Fisman 1981: A double-blind placebo-controlled trial studied 27 people with Alzheimer's disease. 6 of 13 in the drug group withdrew within 5 weeks because of side effects; no significant benefit was found. Reported problems included drowsiness, slowing, increased confusion and mild blood-pressure elevation. The abstract does not verify randomization; 6/13 is not the adverse-event rate for all users. It does not justify self-directed dose reduction or timing advice. Fisher 2001: Mouse embryos exposed in vitro to 250–750 µM DMAE for 26 hours developed facial and neural-tube defects. This is not an oral-dose trial in pregnant humans; human risk magnitude or a safe dose cannot be calculated. It gives no reassurance for self-use in pregnancy. Use with neurological/psychiatric illness or medicines needs clinical assessment; missing interaction records do not mean safe.
Sale and import status in Türkiye must be checked for the specific product. Verify supplement approval in the Ministry of Agriculture and Forestry GGBS list, and medicine authorization and conditions of use in TİTCK records. Online availability does not establish approval or unrestricted personal import; current Ministry of Trade conditions apply to postal and express shipments.
No established timeframe